Karolinska Development’s portfolio company Dilafor advances tafoxiparin following successful meetings with FDA and European regulatory authorities
KDEV) today announces that its portfolio company Dilafor has successfully completed regulatory meetings with the U.S. Food and Drug Administration, FDA, and European Health Agencies, regarding the ...
PHAXIAM Provides An Update On The Deployment Of Its Strategy To Maximize The Development Potential Of Phage Therapy
PHAXIAM Therapeutics (Euronext: PHXM - FR0011471135), a biopharmaceutical company ("PHAXIAM" or "the Company") developing innovative treatments for severe and resistant bacterial infections, announced ...
BioWorld7h
Stereotaxis begins anew with Genesisx launch in EU
Continuing a cascade of positive news for Stereotaxis Inc., the company reported the first order for its petite Genesisx robot in Europe. The system received CE mark in August, but management held off ...
securingindustry.com11h
Europol issues warning over online drug purchases
A crackdown on the sale of counterfeit medicines online, coordinated by Europol, has resulted in the seizure of items worth ...